Nabriva Therapeutics PLC expected to post a loss of $4.02 a share - Earnings Preview

Nabriva Therapeutics

09/11/2022 02:11

* Nabriva Therapeutics PLC  NBRV.OQ   NBRV.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
10. 
    * The Dublin Ireland; Republic of-based   company is
expected to
report  a 20.5% increase in revenue to $10.675 million from
$8.86 million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Nabriva
Therapeutics PLC
is for a loss of $4.02 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $18​, above​ its last closing price
of $2.25. ​​​

This summary was machine generated November 9 at 02:11 GMT.  All
figures in US dollars  unless otherwise stated